BRPI0818605A2 - Derivados de 1,3,4-tiadiazl espiro-condensados para inibir a atividade de ksp cinesima - Google Patents

Derivados de 1,3,4-tiadiazl espiro-condensados para inibir a atividade de ksp cinesima

Info

Publication number
BRPI0818605A2
BRPI0818605A2 BRPI0818605A BRPI0818605A2 BR PI0818605 A2 BRPI0818605 A2 BR PI0818605A2 BR PI0818605 A BRPI0818605 A BR PI0818605A BR PI0818605 A2 BRPI0818605 A2 BR PI0818605A2
Authority
BR
Brazil
Prior art keywords
tiadiazl
kinesima
esp
condensed
inhibit
Prior art date
Application number
Other languages
English (en)
Inventor
M Arshad Siddiqui
Chaoyang Dai
Umar Faruk Mansoor
Liping Yang
Lalanthi Dilrukshi Vitharana
Angie R Angeles
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40220231&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0818605(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of BRPI0818605A2 publication Critical patent/BRPI0818605A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0818605 2007-10-19 2008-10-16 Derivados de 1,3,4-tiadiazl espiro-condensados para inibir a atividade de ksp cinesima BRPI0818605A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98128807P 2007-10-19 2007-10-19
PCT/US2008/080164 WO2009052288A1 (en) 2007-10-19 2008-10-16 Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity

Publications (1)

Publication Number Publication Date
BRPI0818605A2 true BRPI0818605A2 (pt) 2015-04-22

Family

ID=40220231

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818605 BRPI0818605A2 (pt) 2007-10-19 2008-10-16 Derivados de 1,3,4-tiadiazl espiro-condensados para inibir a atividade de ksp cinesima

Country Status (19)

Country Link
US (1) US8796460B2 (pt)
EP (1) EP2220061B1 (pt)
JP (1) JP5455915B2 (pt)
KR (1) KR20100072267A (pt)
CN (2) CN103694258B (pt)
AR (1) AR068888A1 (pt)
AU (1) AU2008312401C1 (pt)
BR (1) BRPI0818605A2 (pt)
CA (1) CA2702922C (pt)
CL (1) CL2008003063A1 (pt)
CO (1) CO6321241A2 (pt)
ES (1) ES2565983T3 (pt)
IL (1) IL205184A0 (pt)
MX (1) MX2010004312A (pt)
PE (1) PE20091349A1 (pt)
RU (1) RU2010119635A (pt)
TW (1) TW200934785A (pt)
WO (1) WO2009052288A1 (pt)
ZA (1) ZA201002701B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
MX2010004026A (es) * 2007-10-19 2010-04-30 Boehringer Ingelheim Int Piperidino-dihidrotienopirimidinas sustituidas.
EP2205609B1 (de) 2007-10-19 2017-03-29 Boehringer Ingelheim International GmbH Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
ATE537175T1 (de) 2007-10-19 2011-12-15 Boehringer Ingelheim Int Neue piperazino-dihydrothienopyrimidin-derivate
US20120070370A1 (en) * 2009-05-13 2012-03-22 Siddiqui M Arshad Spiro 1,3,4-thiadiazoline derivatives as ksp inhibitors
WO2011128388A2 (en) * 2010-04-15 2011-10-20 Novartis Ag Oxazole and thiazole compounds as ksp inhibitors
EP2582682B1 (en) 2010-06-17 2015-01-14 Cytokinetics, Inc. Mitotic kinesin inhibitors for use in the treatmetnof pulmonary arterial hypertension
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
CA2846860A1 (en) 2011-08-30 2013-03-07 Wayne State University Therapeutic compounds and methods
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
CN110041349B (zh) * 2019-05-15 2021-06-01 湖南科技大学 一种含螺二氢嘧啶衍生物及其制备方法和应用
CN111529525A (zh) * 2020-05-15 2020-08-14 淮安市厚沐医疗技术咨询中心 一种Gab1抑制剂用于治疗胆管癌的用途
CN111358786A (zh) * 2020-05-15 2020-07-03 淮安市厚沐医疗技术咨询中心 一种Gab1抑制剂在治疗胆管癌方面的应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051854A1 (fr) * 2001-12-11 2003-06-26 Kyowa Hakko Kogyo Co., Ltd. Dérivé de thiadiazolines
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
EP1515724B1 (en) 2002-06-14 2009-10-21 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2004037171A2 (en) 2002-10-18 2004-05-06 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2509212A1 (en) 2002-12-20 2004-07-15 Merck & Co., Inc. Mitotic kinesin inhibitors
US7622489B2 (en) 2002-12-20 2009-11-24 Merck & Co., Inc. Mitotic kinesin inhibitors
US20040192739A1 (en) * 2003-01-16 2004-09-30 David Solow-Cordero Methods of treating conditions associated with an Edg-2 receptor
AR050920A1 (es) 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
WO2004087050A2 (en) 2003-03-28 2004-10-14 Merck & Co., Inc. Mitotic kinesin inhibitors
ES2377498T3 (es) 2003-04-18 2012-03-28 Kyowa Hakko Kirin Co., Ltd. Inhibidor de quinesina en etapa M
WO2004111023A1 (ja) 2003-06-10 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. チアジアゾリン－１－オキシド誘導体
WO2004111193A2 (en) 2003-06-12 2004-12-23 Merck & Co., Inc. Prodrugs of mitotic kinesin inhibitors
AU2004249138B2 (en) * 2003-06-12 2008-07-17 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
WO2005018638A1 (en) 2003-08-13 2005-03-03 Merck & Co., Inc. Mitotic kinesin inhibitors
PE20050730A1 (es) 2003-08-15 2005-09-20 Merck & Co Inc Derivados de 2,5-dihidropirrol 2,2-disustituidos como inhibidores de quinesinas mitoticas
JP2007502773A (ja) 2003-08-15 2007-02-15 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害薬
WO2005017190A2 (en) 2003-08-15 2005-02-24 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1664026B1 (en) 2003-08-15 2009-01-21 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2005035512A1 (ja) 2003-10-10 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. チアジアゾリン誘導体
US7625912B2 (en) * 2003-12-19 2009-12-01 Merck & Co. Inc Mitotic kinesin inhibitors
CN1934066A (zh) 2004-03-22 2007-03-21 默克公司 有丝分裂驱动蛋白抑制剂
US20070225499A1 (en) 2004-04-19 2007-09-27 Gary Javadi Process for the Preparation of 2,2-Disubstituted Pyrroles
DE102004021637A1 (de) 2004-05-03 2005-12-01 Merck Patent Gmbh Dihydrobenzothiophene
DE102004031656A1 (de) 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
CA2571572A1 (en) 2004-07-01 2006-01-19 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1765830B1 (en) 2004-07-01 2010-09-22 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
AU2005262379A1 (en) 2004-07-01 2006-01-19 Merck Sharp & Dohme Corp. Prodrugs of mitotic kinesin inhibitors
AU2005262383A1 (en) 2004-07-01 2006-01-19 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
WO2006008523A1 (en) 2004-07-22 2006-01-26 Astrazeneca Ab Fused pyrimidones usefuel in the treatment and the prevention of cancer
WO2006023083A1 (en) 2004-08-12 2006-03-02 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1781286A4 (en) 2004-08-18 2009-06-10 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
KR20070046175A (ko) 2004-08-18 2007-05-02 아스트라제네카 아베 선택된 융합 복소환 및 이의 용도
CN101076335A (zh) 2004-08-18 2007-11-21 默克公司 有丝分裂驱动蛋白抑制剂
WO2006031607A2 (en) 2004-09-13 2006-03-23 Merck & Co., Inc. A method of treating cancer
US7449486B2 (en) * 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
CA2589827A1 (en) 2004-12-21 2006-06-29 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2008530094A (ja) 2005-02-10 2008-08-07 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
DE102005010000A1 (de) 2005-03-04 2006-09-07 Merck Patent Gmbh Indane
US7608643B2 (en) 2005-03-09 2009-10-27 Schering Corporation Compounds for inhibiting KSP kinesin activity
EP1863571A1 (en) 2005-03-09 2007-12-12 Shering Corporation Compounds for inhibiting ksp kinesin activity
JP2008533018A (ja) 2005-03-09 2008-08-21 シェーリング コーポレイション ＫＳＰキネシン活性を阻害するための縮合チエノ［２，３−ｂ］ピリジン化合物および縮合チアゾロ［５，４−ｂ］ピリジン化合物
CA2599436A1 (en) 2005-03-16 2006-09-28 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2008533144A (ja) 2005-03-16 2008-08-21 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
JP2008137893A (ja) 2005-03-22 2008-06-19 Kyowa Hakko Kogyo Co Ltd 関節炎治療剤
EP1870404A4 (en) 2005-03-22 2010-07-14 Kyowa Hakko Kirin Co Ltd MEANS FOR THE TREATMENT OF A HEMATOPOIETIC TUMOR
JP2008150291A (ja) 2005-03-22 2008-07-03 Kyowa Hakko Kogyo Co Ltd 乾癬治療剤
JP5060285B2 (ja) 2005-03-22 2012-10-31 協和発酵キリン株式会社 固形腫瘍治療剤
EP1868601A4 (en) 2005-04-07 2008-12-10 Merck & Co Inc MITOTIC KINESINE HEMMER
UA95907C2 (en) * 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
DE102005027170A1 (de) 2005-06-13 2006-12-14 Merck Patent Gmbh Substituierte Tetrahydrochinoline
DE102005027168A1 (de) 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinoline
DE102005027169A1 (de) 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinolinderivate
EP1908755A4 (en) 2005-06-24 2009-06-24 Kyowa Hakko Kirin Co Ltd THERAPEUTIC AGENT AGAINST RESTENOSIS
TW200800951A (en) 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
CN101490061A (zh) * 2006-06-09 2009-07-22 惠氏公司 噻二唑化合物和其使用方法
JP2010505870A (ja) 2006-10-03 2010-02-25 アレイ バイオファーマ、インコーポレイテッド 有糸分裂キネシン阻害剤としてのオキサジアゾール誘導体およびチアジアゾール誘導体、ならびにそれらの使用方法
US20110171172A1 (en) * 2007-11-07 2011-07-14 Siddiqui M Arshad Compounds for inhibiting ksp kinesin activity
CN101903343A (zh) 2007-11-09 2010-12-01 先灵公司 用于抑制ksp驱动蛋白活性的化合物
CL2008003062A1 (es) * 2007-11-09 2010-02-19 Schering Corp Compuestos derivados de pirazoles espiro conjugados, inhibidores de la actividad de ksp kinesina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
US20120070370A1 (en) * 2009-05-13 2012-03-22 Siddiqui M Arshad Spiro 1,3,4-thiadiazoline derivatives as ksp inhibitors

Also Published As

Publication number Publication date
AU2008312401B2 (en) 2014-03-06
CN103694258B (zh) 2016-01-13
US8796460B2 (en) 2014-08-05
EP2220061A1 (en) 2010-08-25
ZA201002701B (en) 2011-04-28
JP2011500714A (ja) 2011-01-06
IL205184A0 (en) 2010-11-30
MX2010004312A (es) 2010-07-05
CN103694258A (zh) 2014-04-02
US20110123435A1 (en) 2011-05-26
WO2009052288A1 (en) 2009-04-23
CA2702922C (en) 2018-01-16
RU2010119635A (ru) 2011-11-27
EP2220061B1 (en) 2016-02-17
CN101903365A (zh) 2010-12-01
AU2008312401C1 (en) 2014-07-10
CN101903365B (zh) 2014-02-05
AR068888A1 (es) 2009-12-16
AU2008312401A1 (en) 2009-04-23
PE20091349A1 (es) 2009-09-07
TW200934785A (en) 2009-08-16
KR20100072267A (ko) 2010-06-30
CA2702922A1 (en) 2009-04-23
ES2565983T3 (es) 2016-04-08
CL2008003063A1 (es) 2010-01-04
JP5455915B2 (ja) 2014-03-26
CO6321241A2 (es) 2011-09-20

Similar Documents

Publication Publication Date Title
BRPI0818605A2 (pt) Derivados de 1,3,4-tiadiazl espiro-condensados para inibir a atividade de ksp cinesima
NO2025029I1 (no) Entrectinib or isomers, tautomers, or pharmaceutically acceptable salts therof - forlenget
NO2016016I2 (no) Lesinurad, eller et farmasøytisk akseptabelt salt derav
BRPI0907563A2 (pt) Derivados de 4,5-di-hidro-xazol-2-il amina
CU24162B1 (es) Derivados 5-aril-1,2,4-triazolona ligada a bisarilo sustituidos
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
HRP20151058T1 (xx) Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
BRPI0811718A2 (pt) Derivados de 3,3-espiroindolinona
DE602008005634D1 (de) 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
BRPI0816970A2 (pt) 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
BRPI0813384A2 (pt) Suspensões de ingrediente ativo em glicerina
BRPI0922949A2 (pt) unidade de recarga para um distribuidor de produto, e, distribuidor
EP1976651A4 (en) ACTIVE, RECONFIGURABLE STRUCTURE FORMING
BRPI0810139A2 (pt) Catalisador para a preparação de metil mercaptano
BRPI0815059A2 (pt) Derivado de 1,3-di-hidroisoindol
BRPI0810586A2 (pt) Aplicação de glicerina para produção de gado
NO20075402L (no) Katalysator
DE602007005796D1 (de) Schneidegerät
BRPI0814155A2 (pt) Cabeça de corte de um escareador
BRPI0818902A2 (pt) Ciclopentanos substituídos tendo atividade de prostaglandina
BRPI0907749A2 (pt) Derivados de 3,8-diaminotetrahidroquinolina
ATE519751T1 (de) Dihydro-benzoäbüä1,4üdiazepin-2-on- sulfonamidderivate
BRPI0819707A2 (pt) Ciclopentanos substituídas tendo atividade de prostaglandina
BRPI0821269A2 (pt) Métodos para inibir a formação de cicatrizes
FI8012U1 (fi) Radan katkaisulaite

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]